The Trump administration this week announced a preliminary trade deal between the United States and Mexico. Under the agreement, which looks to update the North American Free Trade Agreement, brand name drug makers will receive 10 years of exclusivity for biologics in addition to more products qualifying for this protection.
The Trump administration this week announced a preliminary trade deal between the United States and Mexico. Under the agreement, which looks to update the North American Free Trade Agreement, brand name drug makers will receive 10 years of exclusivity for biologics in addition to more products qualifying for this protection.
Conversely, generic drug makers strongly oppose the deal as it lengthens the current period of exclusivity in Mexico—at the moment, Mexico’s period of exclusivity for biologics is just 5 years.
“This provision would harm the growing biosimilar industry, which aims to provide price competition to some of the most expensive prescription drugs and allow patients to benefit from affordable medicines,” according to a statement from the Association for Accessible Medicines. “The [United States], Mexico, and Canada should reject these provisions, which would benefit brand-name drug companies to the detriment of public health and the affordability of medical care.”
However, brand-name drug manufacturers actually pushed for the policy to include 12 years of protection, as it currently stands in the United States.
“We encourage the administration to continue pushing for strong trade deals that protect and value the life-saving medicines our companies develop and deliver to patients,” said trade industry group PhRMA in a statement. “We look forward to finalizing the text of the agreement once completed to ensure it includes policies that protect against global free-riding, promote research and development, and reward the innovation being pioneered by America’s biopharmaceutical companies for patients across the globe.”
Though the new agreement is not final, the president of Mexico, Enrique Peña-Nieto has emphasized the importance of Canada joining the deal as well. Canadian Foreign Minister Chrystia Freeland arrived in Washington, DC late this past Tuesday, and it thus far remains unclear whether a trilateral agreement will be reached.
The White House will have to send a formal trade agreement to Congress within 30 days, at which point Congress would have an additional 60 days to review the completed deal before the Mexican government potentially approves it in late November, before its new president takes office on December 1.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in New Zealand in 2022.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).